This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
March 09, 2012 4:30 pm ET
Jay Carlson -
Steven W. King - Chief Executive Officer, President, Director, Chief Executive Officer of Avid Bioservices Inc and President of Avid Bioservices Inc
Joseph S. Shan - Vice President of Clinical & Regulatory Affairs
Robert Garnick - Head of Regulatory Affairs
Paul J. Lytle - Chief Financial Officer, Principal Accounting Officer, Corporate Secretary, Chief Financial Officer of Avid Bioservices and Corporate Secretary of Avid Bioservices
Charles C. Duncan - JMP Securities LLC, Research Division
Joseph Pantginis - Roth Capital Partners, LLC, Research Division
Edward H. Nash - Cowen and Company, LLC, Research Division
George B. Zavoico - McNicoll, Lewis & Vlak LLC, Research Division
Stephen M. Dunn - LifeTech Capital, Research Division
David Brian Musket - ProMed Management, Inc.
Good day, ladies and gentlemen, and welcome to the Peregrine Pharmaceuticals Third Quarter Fiscal Year 2012 Financial Results Conference Call. [Operator Instructions] As a reminder, this program is being recorded. I would now like to introduce your host for today's program, Mr. Jay Carlson, Manager of Investor Relations. Please go ahead, sir.
Thanks, Jonathan. Good afternoon, and thank you for joining us. On today's call, we have Steve King, President and Chief Executive Officer; Paul Lytle, Chief Financial Officer; Joe Shan, Vice President of Clinical and Regulatory Affairs; and Rob Garnick, Head of Regulatory Affairs.
Steve will begin by providing an overview of our clinical progress over the last quarter and highlight what will be numerous near-term clinical data milestones. Joe and Rob will discuss our clinical and regulatory plans as we advance our 3 Phase II clinical programs for bavituximab and Cotara. Paul will then finish with a summary of our financial results for the third quarter 2012. After our prepared remarks, we welcome your questions.